Social Icons

Friday 21 August 2015

expr:content='data:blog.blogId' itemprop='blogId'/>

Opening Bell 21-Aug-2015

CS OPENING BELL:
NIFTY SPOT DOWN 122@8251
SENSEX DOWN 404@27205
BANK NIFTY FUTURES DOWN 265@18045

HAPPY TRADING
+917316790000

CS NIFTY FUTURES (AUG) OVERVIEW
TREND MIXED TO BEARISH
RES2:8455
RES 1:8420     
SUP1:8325
SUP2:8295

--------------------------------------------------------------------

CS BANK NIFTY FUTURES (AUGUST) OVERVIEW
TREND MIXED TO BEARISH
RES 2:18525
RES 1:18435
SUP1:18215
SUP2:18125


Thursday 20 August 2015

expr:content='data:blog.blogId' itemprop='blogId'/>

INDIAN BENCHMARKS posts biggest

INDIAN BENCHMARKS posts biggest single-day fall in nearly 4 weeks
                                                                   
INDIAN EQUITY BENCHMARKS  fell about 1.5 percent amid global risk aversion, while Infosys declined on speculation that it may announce acquisitions which may weigh on its earnings. The S&P BSE Sensex and CNX Nifty ended 1.16%-1.44% lower each.

Headlines for the day:

  • Crude oil declines further; Brent at $47
  • S&P BSE Metal index drops by 2%
  • Q1FY2016 IT earnings review
  • Q1FY2016 Auto earnings review                                                

                                                                    

The crucial resistance for Nifty is now seen at 8420 and above this 8455. Support for the immediate term is now placed at 8325 and next support will be 8295.

expr:content='data:blog.blogId' itemprop='blogId'/>

Closing Bell 20-Aug


CS CLOSING BELL:
NIFTY SPOT DOWN 122@8372
SENSEX DOWN 322@27607
BANK NIFTY FUTURES DOWN 400@18325

HAVE A NICE DAY!
WWW.CAPITALSTARS.COM 
+917316790000

DAILY NIFTY SMART MOVERS


SCRIPTS
PRICE
VOLUME             (IN 000’S)
PRE. CLOSE
CHANGE (%)
CHANGE (Rs.)
1893.00
3294.08
1795.40
5.44
97.60
328.55
11828.57
316.90
3.68
11.65
902.90
2734.80
887.10
1.78
15.80
4298.90
659.77
4231.30
1.60
67.60
937.35
7361.27
927.75
1.03
9.60


 DAILY NIFTY TOP LAGGARDS                     


SCRIPTS
PRICE
VOLUME (000’S)
PRE. CLOSE
CHANGE (%)
CHANGE (Rs.)
141.65
3552.61
151.60
-6.56
-9.95
724.00
6617.88
774.25
-6.49
-50.25
159.10
4208.30
168.00
-5.30
-8.90
98.30
10619.08
102.50
-4.10
-4.20
916.25
4170.66
954.60
-4.02
-38.35
expr:content='data:blog.blogId' itemprop='blogId'/>

Corporate News For Today 20-Aug-2015

·         Aurobindo gets final approval for Omeprazole
Aurobindo Pharma announced that the company has received the final approval from the US Food & Drug Administration ( USFDA) to manufacture and market Omeprazole Delayed-release Capsules USP, 10mg, 20mg and 40mg. The approved ANDA is bioequivalent and therapeutically equivalent to the reference listed drug product (RLD) Prilosec® Delayed-release Capsules, 10mg, 20mg and 40mg of AstraZeneca Pharmaceuticals.

·          Aurobindo receives USFDA approval for Ibandronate
Aurobindo Pharma announced that the company has received final approvals from the US Food & Drug Administration ( USFDA) to manufacture and market Ibandronate Sodium Injection, 3mg/3mL (1mg/mL).
Ibandronate Sodium Injection, 3mg/3mL (1mg/mL) is bioequivalent and therapeutically equivalent to the reference listed drug product (RLD) Boniva® Injection, 3mg/3mL (1mg/mL) of Hoffmann-La Roche, Inc. Ibandronate Sodium Injection is indicated for the treatment of osteoporosis in postmenopausal women.
                                                                                
·         Crude oil declines further; Brent at $47
Crude oil declined further; Brent at $47 and WTI at $ 40, new low - Positive for OMC’s , Paints, Lubricants and Tyre companies .Crude Oil ( Brent) has slipped again and is now trading below 5 year low at $ 46.92, while WTI Oil is hovering around $40. As a result the industries which use crude and its derivatives are expected to be beneficial. Positive for OMCs (HPCL, BPCL), Paint (Asian Paints) and lubricants (Castrol, Gulf oil lubricant)
·         Lupin gets USFDA nod for Fenofibrate tablets; stk jumps
Shares of Lupin surged over 8%, touching to Rs1939.9, after pharma major said it has received approval from USFDA for Fenofibrate tablets in dosages of 160 mg and 54 mg. Fenofibrate is mainly used to reduce cholesterol levels in patients at risk of cardiovascular disease. Like other fibrates, it reduces both low-density lipoprotein (LDL) and very low density lipoprotein (VLDL) levels, as well as increasing high-density lipoprotein (HDL) levels and reducing triglyceride levels.

·         Ratnamani Metals bags new order worth Rs159.40 cr
Ratnamani Metals & Tubes has announced that the Company has bagged an order for supply of coated CS pipes from Reliance Gas Pipelines amounting to Rs159.40 crores (net of taxes and duties) to be completed in current financial year.

·         Somi Conveyor Beltings receives orders worth Rs40.14 cr
Somi Conveyor Beltings said that it has received purchase orders worth Rs40.137 crore from BHEL, L&T and ThyssenKrupp Industries. The company will supply conveyor belts and related material of various specifications, it said. The company has bagged order worth Rs14.751 crore from Bharat Heavy Electricals ( BHEL). The order worth Rs14.164 crore was received from Larsen & Tourbo ( L&T), it said.
In addition, ThyssenKrupp Industries India issued order worth Rs 11.222 million to the company.
                                                                                                   
·         JSW Steel to invest Rs5000 cr on capital expenditure
JSW Steel has said that it is planning to invest about Rs5,000 crore on various capital expenditure projects in this fiscal ending March 2016, as per reports.  Commenting on the issue, JSW Steel Chairman and Managing Director Sajjan Jindal told the media, 'The company is expected to invest approximately Rs 5,000 crore during FY16 on various capital expenditure programmes.'
                                                    
·         Sun Pharma gets USFDA approval for Ximino

Sun Pharma gets USFDA approval for Ximino: Positive for the company .Sun Pharma gets US FDA approval for Supplemental New Drug Application (sNDA) for Ximino. This approval further strengthens the Company’s branded dermatology portfolio in the US. It expects Ximino TM extended-release capsules to be available for patients during the fourth quarter of 2015.
 

Do U Want !!!!

Our Special Services

sensex-nifty-charts

 
Blogger Templates